Biotech business development is one of the most relationship-driven, information-intensive functions in life sciences. BD teams at early and mid-stage biotechs are responsible for identifying licensing opportunities, structuring partnership term sheets, managing investor outreach, and running the due diligence processes that determine whether a program advances or stalls. At the same time, most biotech BD departments are small — often two to five people managing a company's entire external deal activity.
The result is a function that is chronically under-resourced relative to its strategic importance. According to a 2023 Deloitte Life Sciences report, deal-making in biopharma reached over $225 billion in disclosed deal value globally, yet the operational teams executing those deals remain lean by industry standards. The gap between deal volume and team capacity is where virtual assistants (VAs) are making an outsized impact.
Conference and Event Pipeline Management
JP Morgan Healthcare, BIO International Convention, and partnering conferences like BIO-Europe are central to biotech BD calendars. These events generate an enormous amount of scheduling, follow-up, and data management work before, during, and after each conference cycle.
VAs can own the logistics layer of conference participation: managing partnering platform registrations (One-on-One, Inova), building meeting request queues, confirming appointments, and preparing pre-meeting briefing packages for each BD team member. Post-conference, VAs track follow-up commitments, log new contact records in the CRM, and send follow-up correspondence on behalf of the BD team.
For a BD team of three managing forty partnering meetings across a three-day conference, having a VA coordinate the pre- and post-conference workflow can save dozens of hours and significantly improve follow-through rates.
Data Room and Due Diligence Coordination
When a licensing or collaboration discussion advances to due diligence, the operational demands on a biotech BD team multiply quickly. Data rooms must be organized and populated, NDAs tracked and filed, and document request lists managed against completion status. BD leads who handle this personally are pulled away from the relationship-building and negotiation work that only they can do.
VAs with experience in virtual data room platforms (Intralinks, Datasite, iDeals) can manage document organization, access provisioning, and request tracking under BD supervision. They can maintain a due diligence checklist, coordinate document retrieval from the scientific and legal teams, and provide regular status updates without requiring the BD lead to monitor the data room daily.
This support is particularly valuable during simultaneous multi-party processes, where a biotech may be running parallel due diligence with several potential partners and the documentation management load is multiplied.
Investor Relations and Communication Coordination
For pre-commercial biotechs, BD and investor relations functions often overlap significantly. BD teams field inbound interest from strategic investors, coordinate roadshow scheduling, and manage outreach campaigns to family offices, crossover investors, and strategic pharma partners simultaneously.
VAs can maintain investor contact databases, track outreach cadences, and prepare meeting summary notes after investor calls. They can also monitor news feeds for relevant portfolio company activity, competitive intelligence, or financing announcements that inform BD strategy — providing the BD lead with a curated morning briefing rather than requiring manual research.
Licensing Agreement Tracking and Milestone Administration
Post-deal, biotech BD teams must monitor licensing agreements for milestone triggers — regulatory submissions, clinical trial initiations, approval decisions — and coordinate royalty reporting and payment processes with finance and legal. For companies with multiple out-licensed programs or in-licensed assets, this becomes a significant ongoing administrative function.
VAs can maintain milestone tracking calendars, prepare quarterly royalty report packages, and coordinate between the finance and legal teams to ensure agreement obligations are met on schedule. This reduces the risk of missed milestone payments or reporting deadlines that could create partnership friction.
Biotech business development companies looking to increase deal velocity and reduce operational drag on their BD teams can find purpose-trained life sciences VAs at Stealth Agents. Their virtual assistants bring relevant industry knowledge and can support BD teams through every phase of the deal lifecycle.
Sources
- Deloitte, 2023 Global Life Sciences Outlook
- BIO International Convention, BIO One-on-One Partnering System Statistics
- Datasite, Life Sciences M&A and Licensing Transaction Report, 2023